SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Lab gets Health Canada’s nod for Generic Semaglutide Injection

29 Apr 2026 Evaluate

Dr. Reddy's Laboratories has received a Notice of Compliance (i.e. an approval) from the Pharmaceutical Drugs Directorate, Canada (Health Canada) regarding its Abbreviated New Drug Submission (ANDS) of Semaglutide Injection (semaglutide). The company becomes the first company to receive the market authorization for generic Semaglutide Injection in Canada, ahead of Health Canada’s review target date. Semaglutide is indicated for the once-weekly treatment of adult patients with type 2 diabetes to improve glycemic control.

The market authorization covers the 2 mg / pen (1.34 mg / mL) and 4 mg / pen (1.34 mg / mL). With launch preparations underway, the company’s is well-positioned to bring this important treatment option available to Canadian patients. Health Canada’s approval demonstrates the company’s expertise in complex generics and peptide-based therapeutics, supported by in-house API as well as formulation development capabilities. The API is entirely produced in-house, with finished product manufacturing currently carried out by the company’s manufacturing partner, OneSource Specialty Pharma.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1322.95 -7.15 (-0.54%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×